Waning immunity to SARS-CoV-2: implications for vaccine booster strategies.
Waning immunity to SARS-CoV-2: implications for vaccine booster strategies.
复制标题
DOI：
10.1016/s2213-2600(21)00458-6
复制
发表时间：
2021-12
期刊：
影响因子：
--
通讯作者：
Boyton RJ
中科院分区：
文献类型：
--
作者：
Altmann DM;Boyton RJ
在2019冠状病毒病大流行的第二年即将结束之际，免疫学家和疫苗学家面临诸多挑战，其中最艰巨的挑战之一是描述保护性免疫的持久性。免疫保护的持续时间对加强疫苗接种计划的实施具有至关重要的意义，包括额外剂量的必要性和时间，这是科学家和决策者之间激烈辩论的一个来源。Gregory Milne及其同事在《柳叶刀呼吸医学》（The Lancet Respiratory Medicine）的一篇个人观点中，回顾了关于自然感染和疫苗接种对SARS-CoV-2的细胞和体液免疫的新数据，并就这些证据在保护性免疫的寿命方面的意义提出了他们的观点。面对许多不确定和争议点，包括与令人关注的SARS-CoV-2变体的出现和疫苗的公平分配有关的问题，卫生政策制定者面临着制定战略以减轻疾病负担的艰巨任务。加强规划需要充足的疫苗储备、国家供应和实施后勤，以及对年龄或风险群体进行优先排序的理由，但也面临更多未知免疫学的挑战，而现有证据基础薄弱：在世界上，加强接种者将来自具有可变先前免疫的人——这可能基于以前的感染，通常与疫苗接种重叠
As we approach the end of the second year of the COVID-19 pandemic, of the many challenges facing immunologists and vaccinologists, one of the toughest has been the characterisation of the durability of protective immunity. The duration of immune protection has crucial implications for the implementation of booster vaccination programmes1—including the need for and timing of additional doses—which are a source of intense debate among both scientists and policy makers. In a Personal View in The Lancet Respiratory Medicine, 2 Gregory Milne and colleagues review emerging data on cellular and humoral immunity to SARS-CoV-2, in response to natural infection and vaccination, and offer their views on what the evidence means in terms of the longevity of protective immunity. Health policy makers have the unenviable task of developing strategies to reduce the burden of disease in the face of many points of uncertainty and controversy, including those related to the emergence of SARS-CoV-2 variants of concern and the equitable distribution of vaccines. Booster programmes require adequate vaccine stocks, national supply and implementation logistics, and a rationale for age or risk-group prioritisation, but also the challenge of yet more uncharted immunology for which the existing evidence base is thin: in a world in which booster recipients will be drawn from those with variable prior immunity—which might be based on previous infection, often overlaid with vaccination with